New Delhi: India's indigenous vaccine maker Bharat Biotech has completed the trial for the third and final phase of the vaccine and has now released its results. Hyderabad-based Bharat Biotech said it has analysed the data for the final phase-3 for Covaxin has been found to be effective on serious corona patients and patients with delta variants.

According to the trial data released by Bharat Biotech, the last phase of trials has found to be 77.8 percent effective against Covaxin corona. On the other hand, the vaccine has been found to be 65.2 percent effective against the dangerous Delta variant. Citing pre-print data, Bharat Biotech said its vaccine is 77.8 percent effective on symptomatic corona patients. On the other hand, Covaxin is 93.4 percent effective against serious corona patients. Bharat Biotech has conducted these trials on 130 corona infected cases.

According to an analysis of its last stage data, the company has said that Covaxin 63.6 percent is effective against asymptomatic corona patients. According to Bharat Biotech, the trial of Covaxin was conducted in 25 different hospitals in the country. It was attended by about 25800 volunteers, aged between 18 and 98 years. Both doses of vaccine were given to those participating in the third phase of trials.

Uttarakhand CM Tirath Singh Rawat resigns, BJP to elect new leader

Couple commits suicide three months after love marriage, know the matter

MLA Akash Kailash Vijayvargiya reaches PC Sethi Hospital to inspect arrangements